BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Bria clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces three clinical poster at the 2026 American Association for Cancer Research (AACR) Annual Meeting, three clinical posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California And this two posters highlighting further analyses of Phase 2 data. 

Principal Investigator of the BriaCell Phase 3 study of Bria-IMT+CPI, and Professor of Oncology, Mayo Clinic. Saranya Chumsri, MD, stated, Standards of care in cancer are evolving rapidly as innovative immunotherapy approaches emerge with potentially better safety profiles than chemotherapy. Clinical data, including BriaCell’s, highlight that maintaining quality of life is an important treatment goal alongside efficacy and safety. 

According to Towards Healthcare, the Metastatic Breast Cancer market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 24.99 billion in 2026 to approximately USD 57.02 billion by 2035, representing a compound annual growth rate (CAGR) of 9.6% from 2026 to 2035. Growth is driven by the prevailing incidence of breast cancer and the need for targeted therapies, with rising metastatic breast cancer burden, the adoption of chemotherapy regimens, the expansion of hormone therapy usage, advancements in radiation techniques, and improved cancer screening programs. 

About BriaCell 

BriaCell Therapeutics Corp. is dedicated to transforming cancer care through novel immunotherapies. The company is currently advancing its lead candidate, Bria-IMT, which is a patented, off-the-shelf, cell-based immunotherapy designed to activate the patient's immune system to specifically target and kill cancer cells without harming healthy cells. 

The company aims to provide personalised treatment options for various cancer types. Positive results from the ongoing studies could lead to significant advancements in treatment options for patients with metastatic breast cancer and potentially other cancers in the future.  

A recent report by Towards Healthcare highlights that the Metastatic Breast Cancer market is witnessing growth due to the focus on increasing incidence of breast cancer and the need for innovative therapeutic solutions. Key growth drivers include advancements in targeted therapies, immunotherapy options, and personalised medicine approaches. This growth is attributed to rising demand for targeted therapies, the development of immunotherapy options, and the focus on personalised treatment pathways.

North America has been the dominant region driven by a combination of factors such as advanced healthcare infrastructure, increased healthcare spending, and evolving reimbursement policies.  

The Asia Pacific region is experiencing significant growth in the metastatic breast cancer market, driven by increasing prevalence rates, advancements in targeted therapies, and expanding healthcare infrastructure.